Enliven Therapeutics Inc. (ELVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 11:05 AM ET
Enliven Therapeutics Inc. (ELVN) Stock Forecast
Analysts expect Enliven Therapeutics (ELVN) to earn -$1.67 per share in the fiscal year ending Dec 31, 2026. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.79, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 21.4% |
| Buy | 11 | 78.6% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.67
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.99
- EPS consensus, revenue $5000
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.67 | -$2.25 to -$1.16 | 8 | N/A | N/A | 10 |
| Dec 31, 2027 | -$1.99 | -$2.43 to -$1.57 | 8 | $5000 | N/A | 10 |
Quarterly Estimates
The EPS consensus rises from -$0.53 for the quarter ending Dec 31, 2026 to -$0.46 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.53 | -$0.68 to -$0.42 | 16 |
| Mar 31, 2027 | -$0.46 | -$0.54 to -$0.42 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.97.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.67 | -$1.91 | -$1.93 | -$1.85 | -$1.97 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.99 | -$2.32 | -$2.35 | -$2.34 | -$2.30 | N/A |
| Quarter ending Mar 31, 2027 | -$0.46 | -$0.53 | -$0.54 | -$0.53 | -$0.54 | N/A |
Frequently Asked Questions About ELVN
What is the ELVN stock forecast?
Consensus analyst estimates put Enliven Therapeutics's EPS at -$1.67 for the fiscal year ending Dec 31, 2026. The consensus rating from 14 analysts is Buy.
How do analysts rate ELVN stock?
Of 14 analysts covering Enliven Therapeutics, 3 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ELVN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.67, with estimates from -$2.25 to -$1.16 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.99, with estimates from -$2.43 to -$1.57 from 8 analysts.
What revenue do analysts expect from Enliven Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5000.
How many analysts cover ELVN?
14 analysts rate Enliven Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ELVN pages: Overview, Earnings, Forecast, Financials, Competitors